STAR Market Pharma 2024 Report Card: Profit Growth for 53%, R&D Spend Hits ¥350M AverageChina Finance Tech in ChinaBeiGene, Biopharma, BioRay Pharmaceutical, EndoPuls Therapeutics, Jiangsu Jindiaok Biotechnology, Junshi Biosciences, Kexing Biopharm, Medicilon, MicroPort EP, Nansin Pharm, Notta & Belle, Profitability, R&D, RemeGen, SinoCellTech, STAR Market, Sunny Pharmatech, Sunshine Guojian Pharmaceutical, Tinavi Medical Technologies, United Imaging Healthcare, Xiangyu Medical, Zhixiang Bio May 6, 2025
